EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Adults With Acid Sphingomyelinase Deficiency Have Sustained Improvements in Clinical Outcomes With up to 5 Years of Olipudase Alfa Enzyme Replacement Therapy: ASCEND Trial Final Results

Melissa P Wasserstein, Carla E Hollak iD, Antonio Barbato iD, Renata C Gallagher, Roberto Giugliani, Norberto Bernardo Guelbert, Julia B Hennermann iD, Takayuki Ikezoe, Robin Lachmann, Olivier Lidove, Paulina Mabe, Eugen Mengel und 9 weitere

Journal of Inherited Metabolic Disease · 2026-05 · 49 (3)

DOI: 10.1002/jimd.70192 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 28.04.2026. Verfasst von Melissa P Wasserstein und 20 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Enzyme Replacement Therapy, Sphingomyelin Phosphodiesterase, Niemann-Pick Disease, Type A. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NICHD NIH HHS, Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acid sphingomyelinase deficiency (ASMD) is a rare debilitating lysosomal storage disease resulting in multisystemic disease manifestations, significant disease burden, and early mortality for some individuals. Enzyme replacement therapy (ERT) with olipudase alfa (Xenpozyme) is the first disease‐specific treatment indicated for noncentral nervous system manifestations of ASMD in children and adults. During the 1‐year primary analysis of the ASCEND placebo‐controlled trial in 36 adults with ASMD, olipudase alfa treatment reduced sphingomyelin storage and was associated with clinically significant improvements relative to placebo in multiple endpoints. An open‐label extension of the ASCEND trial followed 35 of 36 adults during olipudase alfa treatment for up to 5 years. Mean time on olipudase alfa was 4.2 ± 1.0 years; mean compliance was 90% ± 13%. During long‐term olipudase alfa treatment, percent predicted diffusing capacity for carbon monoxide (DL CO ) increased (mean 50.1% ± 10.8% at baseline vs. 66.5% ± 13.3% at final assessment; mean change from baseline of 35.9% ± 27.5% ( p < 0.0001). Mean baseline spleen volume of 11.5 ± 4.6 multiples of normal (MN) decreased to 4.8 ± 2.1 MN at final assessment, mean change from baseline −57.5% ± 10.1% ( p < 0.0001) and mean baseline liver volume (1.5 ± 0.4 MN) decreased to 0.95 ± 0.23 MN at final assessment, (mean change from baseline −36.8% ± 11.5%, p < 0.0001). Plasma lyso‐sphingomyelin levels decreased by 72% from baseline to final assessment. Overall, improvements in clinical parameters occurred regardless of baseline severity. No new safety issues emerged during the trial extension and 98% of treatment emergent adverse events were mild/moderate. Improvements in visceral ASMD disease with olipudase alfa treatment will significantly impact the disease burden for those with this progressive multiorgan disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enzyme Replacement TherapySphingomyelin PhosphodiesteraseNiemann-Pick Disease, Type AHumansAdultFemaleTreatment OutcomeMaleRecombinant ProteinsMiddle AgedYoung Adult

Stichwörter der Autor:innen

Niemann‐pick type A/BNiemann‐pick type Bchronic acid sphingomyelinase deficiencyhepatopathyinterstitial lung diseaserecombinant human acid sphingomyelinasesplenomegaly

Substanzen

Sphingomyelin Phosphodiesteraseolipudase alfaRecombinant Proteins

Autor:innen und Institutionen

  • Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Department of Endocrinology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy.
  • Department of Pediatrics, University of California San Francisco, San Francisco, California, USA.
  • UFRGS, HCPA, INAGEMP, DASA and Casa dos Raros, Porto Alegre, Brazil.
  • Reina Fabiola University Clinic, Córdoba, Argentina.

ORCID-Profile: Carla E Hollak, Antonio Barbato, Julia B Hennermann

Förderung

  • NICHD NIH HHS
  • Sanofi

Zitieren

APA

Wasserstein, M. P., Hollak, C. E., Barbato, A., Gallagher, R. C., Giugliani, R., Guelbert, N. B., Hennermann, J. B., Ikezoe, T., Lachmann, R., Lidove, O., Mabe, P., Mengel, E., Scarpa, M., Senates, E., Tchan, M., Thurberg, B. L., Villarrubia, J., Armstrong, N. M., Bhushan, S., …, & Kumar, M. (2026). Adults With Acid Sphingomyelinase Deficiency Have Sustained Improvements in Clinical Outcomes With up to 5 Years of Olipudase Alfa Enzyme Replacement Therapy: ASCEND Trial Final Results. Journal of Inherited Metabolic Disease, 49(3). https://doi.org/10.1002/jimd.70192

Vancouver

Wasserstein MP, Hollak CE, Barbato A, Gallagher RC, Giugliani R, Guelbert NB, et al. Adults With Acid Sphingomyelinase Deficiency Have Sustained Improvements in Clinical Outcomes With up to 5 Years of Olipudase Alfa Enzyme Replacement Therapy: ASCEND Trial Final Results. Journal of Inherited Metabolic Disease. 2026;49(3). doi:10.1002/jimd.70192

BibTeX
@article{Wasserstein2026,
  author = {Wasserstein, Melissa P and Hollak, Carla E and Barbato, Antonio and Gallagher, Renata C and Giugliani, Roberto and Guelbert, Norberto Bernardo and Hennermann, Julia B and Ikezoe, Takayuki and Lachmann, Robin and Lidove, Olivier and Mabe, Paulina and Mengel, Eugen and Scarpa, Maurizio and Senates, Ebubekir and Tchan, Michel and Thurberg, Beth L and Villarrubia, Jesus and Armstrong, Nicole M and Bhushan, Shashi and Kim, Yong and Kumar, Monica},
  title = {Adults With Acid Sphingomyelinase Deficiency Have Sustained Improvements in Clinical Outcomes With up to 5 Years of Olipudase Alfa Enzyme Replacement Therapy: ASCEND Trial Final Results},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2026},
  volume = {49},
  number = {3},
  doi = {10.1002/jimd.70192}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche